Consistency of response across subgroups of patients with psoriasis treated with guselkumab: Results from the VOYAGE 1 and 2 trials

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Reich, Kristian [2 ]
Papp, Kim A. [3 ]
Griffiths, Christopher E. M. [4 ]
Armstrong, April W. [5 ]
Foley, Peter [6 ,7 ]
Shen, Yaung-Kaung [8 ]
Kimball, Alexa B. [9 ]
Gordon, Kenneth B. [10 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Dermatologikum Hamburg, Hamburg, Germany
[3] K Papp Clin Res & Prob Res Inc, Waterloo, ON, Canada
[4] Univ Manchester, Manchester Acad Hlth Sci Ctr, Salford Royal Hosp, Dermatol Ctr, Manchester, Lancs, England
[5] Univ Southern Calif, Los Angeles, CA USA
[6] Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia
[7] Skin & Canc Fdn Inc, Carlton, Vic, Australia
[8] Janssen Res & Dev LLC, Raritan, NJ USA
[9] Harvard Med Sch, Dept Dermatol, Boston, MA USA
[10] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2017年 / 76卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
4895
引用
收藏
页码：AB83 / AB83
页数：1
相关论文
共 50 条
  • [21] Safety of guselkumab in patients with plaque psoriasis through 2 years: a pooled analysis from VOYAGE 1 and VOYAGE 2
    Reich, K.
    Papp, K.
    Armstrong, A. W.
    Wasfi, Y.
    Jiang, G.
    Shen, Y-K.
    Randazzo, B.
    Song, M.
    Kimball, A. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E297 - E297
  • [22] Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2
    Kim, Byung Soo
    Jo, Seong Jin
    Youn, Sangwoong
    Reich, Kristian
    Saadoun, Carine
    Chang, Chia-Ling
    Yang, Ya-Wen
    Huang, Yu-Huei
    Tsai, Tsen-Fang
    DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2721 - 2737
  • [23] Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2
    Byung Soo Kim
    Seong Jin Jo
    SangWoong Youn
    Kristian Reich
    Carine Saadoun
    Chia-Ling Chang
    Ya-Wen Yang
    Yu-Huei Huang
    Tsen-Fang Tsai
    Dermatology and Therapy, 2023, 13 : 2721 - 2737
  • [24] Efficacy responses across subgroups of patients with moderate-to-severe plaque psoriasis treated with guselkumab, an anti-interleukin-23p19 monoclonal antibody: results from VOYAGE 1 through 5 years
    Thaci, D.
    Foley, P.
    Puig, L.
    Merola, J. F.
    Miller, M.
    You, Y.
    Shen, Y. -K.
    Yang, Y. -W.
    Blauvelt, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E51 - E51
  • [25] The Impact of Treatment with Guselkumab on Skin-related Quality of Life in Male and Female Patients with Moderate to Severe Psoriasis: Results from the VOYAGE 1 and 2 Trials
    Armstrong, April
    Puig, Luis
    Papp, Kim A.
    Strauss, Marcie E.
    Yang, Ya-Wen
    Cheng, Ru-Fong
    Miller, Megan
    Murase, Jenny E.
    Fernandez-Penas, Pablo
    Han, Chenglong
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB235 - AB235
  • [26] Malignancy rates through 5 years of follow-up in guselkumab-treated patients with moderate to severe psoriasis: Results from the VOYAGE 1 and 2 trials and comparisons to general populations
    Blauvelt, Andrew
    Langley, Richard G.
    Ho, Vincent
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB79 - AB79
  • [27] Guselkumab efficacy and safety through 5 years among psoriasis patients with and without metabolic syndrome at baseline: Results from VOYAGE 1 and VOYAGE 2
    Merola, Joseph F.
    Thaci, Diamant
    Choi, Olivia
    Chan, Daphne
    Yang, Ya-Wen
    Miller, Megan
    You, Yin
    Li, Shu
    Blauvelt, Andrew
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB170 - AB170
  • [28] Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials
    Reich, Kristian
    Griffiths, Christopher E. M.
    Gordon, Kenneth B.
    Papp, Kim A.
    Song, Michael
    Randazzo, Bruce
    Li, Shu
    Shen, Yaung-Kaung
    Han, Chenglong
    Kimball, Alexa B.
    Armstrong, April W.
    Foley, Peter
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (04) : 936 - 945
  • [29] Clinical response after guselkumab treatment among adalimumab PASI 90 nonresponders: Results from the VOYAGE 1 and 2 trials
    Griffiths, Christopher E. M.
    Radtke, Marc Alexander
    Youn, Sang Woong
    Bissonnette, Robert
    Song, Michael
    Wasfi, Yasmine
    Randazzo, Bruce
    You, Yin
    Shen, Yaung-Kaung
    Strober, Bruce
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB78 - AB78
  • [30] Low-risk of serious infections and infections of interest in psoriasis patients treated with Guselkumab for 5 years in VOYAGE 1 and 2 phase 3 trials
    Langley, R.
    Thaci, D.
    Blauvelt, A.
    Tsai, T. -F.
    Miller, M.
    Yu, J.
    Shen, Y. -K.
    You, Y.
    Yang, Y. -W.
    Papp, K. A.
    Puig, L.
    Foley, P.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 35 - 35
12345